Crinetics Pharmaceuticals, Inc.
CRNX
株式のランク
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
株価
$84.95
最終同期: 2026-09-01
時価総額
$9.00B
変化（1日）
0.00%
変化（1年）
98.25%
国
US
取引 Crinetics Pharmaceuticals, Inc. (CRNX)
カテゴリー
Healthcare
Crinetics Pharmaceuticals, Inc.（CRNX）の発行済株式数
June 2026 時点の発行済株式数 105.56M
Crinetics Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 105.56M です。December 2023 の終わりには、同社は 58.07M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Crinetics Pharmaceuticals, Inc.（CRNX）の発行済株式数の履歴（2016 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 105.56M | 30.67% |
| 2024 | 80.78M | 39.11% |
| 2023 | 58.07M | 11.71% |
| 2022 | 51.98M | 35.24% |
| 2021 | 38.44M | 26.23% |
| 2020 | 30.45M | 25.95% |
| 2019 | 24.18M | 99.10% |
| 2018 | 12.14M | -12.51% |
| 2017 | 13.88M | 0.00% |
| 2016 | 13.88M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 140.53% |
US
|
|
| 396.00M | 275.14% |
US
|
|
| 478.91M | 353.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -41.09% |
NL
|
